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ABSTRACT
Vitronectin is a glycoprotein involved in many cellular processes including blood
coagulation, fibrinolysis, and cell/matrix binding.

It interacts with a number of

macromolecules including heparin, PAI-1, and the thrombin-antithrombin complex. We
have studied the interaction of full-length vitronectin and the thrombin-antithrombin
complex using a Far Western method. To localize the recognition site for thrombinantithrombin binding to vitronectin, sequences for eight overlapping recombinant
polypeptide sequences of vitronectin (spanning all 459 amino acids) were cloned into the
pET system. Expression in BL21(DE3)pLysS Escherichia coli has been achieved for
seven of the eight 100 amino acid fragments. Seven polypeptides (amino acids 1-100,
51-150, 101-200, 151-250, 201-300, 251-350, and 351-459) have been isolated and
purified using metal-chelating affinity chromatography.

These fragments have been

tested for interaction with the thrombin-antithrombin pair using the Far Western
technique. Results indicate interaction of the complex with vitronectin between amino
acids 201-300 and possibly at another site near the C-terminal. Additionally, these
expressed fragments have served as helpful reagents in mapping the epitopes of three
monoclonal antibodies for vitronectin.
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Part A
Vitronectin: An Overview of Function, Organization, and Structure
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I. Introduction
Vitronectin is an adhesive glycoprotein found in both circulation and the
extracellular matrix (ECM). It is involved in a number of physiological processes
including blood coagulation, fibrinolysis, cellular migration, the humoral immune
response, tumor metastasis, and angiogenesis (1,2). Its importance as a regulatory
protein, particularly in maintaining the fine balance between thrombus formation and
dissolution, cannot be over-emphasized. Disruption of this balance can result in
excessive bleeding, disseminated intravascular coagulation, stroke, or myocardial
infarction .
Vitronectin plays its diverse and important role in vivo by binding a vast array of
biological ligands. These include heparin (3-5), plasminogen activator inhibitor-1 (PAI1) (6-10), proteases such as the urokinase-type plasminogen activator (uPA) (11),
constituents of the extracellular matrix such as collagen (12), the terminal complement
complex (13,14), and the thrombin-antithrombin (TAT) pair (11,15-17). A number of
methods have been employed to determine the number of binding sites and the region(s)
or residues involved in the interaction of vitronectin with its various ligands. These
methods include 1) binding studies using synthetic peptides; 2) experiments with
cleavage products created via chemical and proteolytic digestion; 3) studies with
monoclonal antibodies; 4) competition assays; 5) investigations involving recombinant
expression of vitronectin polypeptides; 6) (photo)affinity labeling; and/or 7) a
combination of these methods. The focus of this proposal centers on the recombinant
expression of polypeptides to localize the vitronectin binding sites involved in the
interaction of the protein with the thrombin-antithrombin complex. The polypeptides are
2

further exploited to epitope map a number of acquired monoclonal antibodies to
vitronectin.

II. Localization and Tissue Distribution
Vitronectin was first identified in 1967 as a serum spreading factor (18). Like
many other plasma proteins, it is synthesized primarily in the liver and generally
identified, like fibronectin, as an acute phase protein (19). It circulates in normal plasma
at concentrations of 200-400 µg/ml (20,21), which constitutes 0.2-0.5% of total plasma
proteins. Non-circulating forms of vitronectin are found in the ECM, and low levels of
vitronectin expression are detected in lung, kidney, sperm, skin, and brain tissue (22,23).
Circulating vitronectin is primarily monomeric, whereas matrix vitronectin and
other tissue-associated forms are predominantly multimeric (20,24). Approximately
0.8% of the circulating pool of vitronectin is contained within platelets in a rapid
releasable form (25-27). Rather than being synthesized by megakaryocytes, platelet
vitronectin is most likely endocytosed from plasma and incorporated into α-granules (28).

III. Vitronectin Function
Vitronectin is diverse in function. As mentioned previously, it is particularly
important in the regulation of hemostasis. In the complex, highly regulated blood
coagulation cascade (Figure A.1), an injury to a vessel wall initiates a series of events
that leads to the eventual conversion of the zymogen prothrombin to the serine protease
thrombin. Thrombin in turn cleaves soluble fibrinogen into insoluble fibrin. Together
with platelet aggregation, a fibrin network works to form the hemostatic plug at the site
3

Blood Coagulation

X
XI

XIIa
XI

XIa
Tissue Factor * VIIa
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Ixa * VIIIa
Xa * Va

Platelets

Figure 1. Blood Coagulation Cascade

Prothrombin

Thrombin
Fibrinogen

Fibrin

Figure A.1: The Blood Coagulation Cascade.
Schematic representing the several steps involved in the proteolytic cleavage of
zymogens into their active forms that eventually lead to the formation of a hemostatic
plug. Inactive prothrombin is converted to active thrombin via Factor Xa and Va.
Thrombin in turn cleaves soluble fibrinogen to form insoluble fibrin, thus initiating clot
formation.
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of injury. Thrombin's proteolytic activity is inhibited by antithrombin, a serine protease
inhibitor (serpin) that forms an inactive protease-inhibitor complex with thrombin (29).
The proteoglycan heparin facilitates this complex formation. Vitronectin plays a procoagulant role by binding heparin, thus neutralizing the ability of heparin to initiate
thrombin-antithrombin pairing (29,30). Vitronectin also binds directly to the thrombinantithrombin complex and clears the inactivated pair from circulation (16,31,32).
Plasminogen activators enzymatically cleave precursor plasminogen to form
active plasmin. Plasmin is the main protein responsible for the degradation of the fibrin
network, defined as fibrinolysis (33). Inhibitors bind and inactivate plasminogen
activators to regulate the fibrinolytic process. Vitronectin plays a key role in this process
by maintaining the inhibitors in their active conformations and localizing them to the clot
surface. The serine protease inhibitor PAI-1 is an important example of an inhibitor of
fibrinolysis that binds vitronectin (9). Indeed, the vitronectin-PAI-1 interaction can be
considered one of the most critical functions of vitronectin. PAI-1 binds plasminogen
activators to form an inactive protease-inhibitor complex, thus blocking plasmin
formation (34,35). PAI-1, however, is intrinsically unstable and converts readily into an
inactive, latent form (Figure A.2) (36). Very importantly, vitronectin binds PAI-1 to
keep it in an active conformation (7,37,38), thus keeping PAI-1 working as an inhibitor
of the fibrinolytic process.
The urokinase plasminogen activator receptor (uPAR) is a glycosylphosphatidyl
inositol (GPI) anchored receptor that has two major ligands—urokinase plasminogen
activator and vitronectin (39,40). Urokinase plasminogen activator (uPA) binds uPAR
with high affinity (41-43). uPA is a highly specific serine protease capable of activating
5

RCL
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b.

Figure A.2: Structure of Active and Latent PAI-1.
The 3D structure of the active form of PAI-1 (a.) illustrates features pertinent to the
inhibitory mechanism of proteases by serpins. Serpins are folded around a large,
central β-sheet (the A sheet) from which protrudes a surface-exposed loop (the
reactive-center loop or RCL). Within this loop region are the residues recognized as
substrates by the target protease (uPA or tPA), with the reactive center peptide bond
denoted P1-P1'. Upon attack of the protease, this P1-P1' peptide bond of PAI-1 is
cleaved by nucleophilic attack of the active-site serine, and an acyl-intermediate is
formed. In contrast to the normal progression of proteolysis, this acyl-intermediate is
extremely long-lived due to a negligible rate of deacylation.
Structural
rearrangements occur so that the two ends of the cleaved loop separate, and the P1
end, with the enzyme covalently coupled, is partially inserted into the central β-sheet.
As such, the protease is inactivated by formation of a 1:1 stable, covalent complex
with the serpin. PAI-1 is unique among the serpins because it readily relaxes from this
active form (a.) to a latent, inactive form (b.). As shown, this occurs by insertion of
the RCL into the central β-sheet to contribute a sixth strand to this secondary
structural element. This refolding is thermodynamically driven, since the latent form
of PAI-1 is more stable.
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plasminogen to plasmin in the process of fibrinolysis previously described, thus it plays a
very important role in tissue remodeling; PAI-1 is its major inhibitor (44). Vitronectin
can bind both membrane-bound and unbound/soluble uPAR (40,45-49) with the
interaction stimulated by uPA occupancy of uPAR . Additionally, uPA/uPAR binding to
vitronectin has been shown to be controlled by uPAR dimerization in vitro (50). The
association of vitronectin with uPAR appears to be partly responsible for spatial
localization of uPAR on the cell surface (51). Through its interaction with matrix
vitronectin, soluble uPAR may still associate with the cell surface and the ECM (52).
Vitronectin can also bind uPA (11). The uPA and uPAR binding sites on vitronectin are
distinct from each other . PAI-1 shares a vitronectin binding site with uPAR and
competes for vitronectin binding; the binding of PAI-1 and uPAR is mutually exclusive
(53-55).
Vitronectin cellular adhesion via uPAR has been observed in monocytes,
fibroblasts, epithelial, and smooth muscle cells (47,56-59). Their interaction causes a
“potent induction” (51) of actin cytoskeleton rearrangement and cell motility (60).
Experiments demonstrate that uPAR mediated cell spreading on vitronectin necessitates
integrin activation and function (61).
Integrins are so named because they “integrate” the cell with the ECM and
perform receptor functions in cell interactions, as well as signal transduction. A typical
integrin consists of an α/β heterodimer and usually binds a number of ligands. Integrins
αVß1, α8ß1, αVß3, αIIbß3, αVß5, and αVß8 have all demonstrated binding to the RGD
sequence of vitronectin (amino acids 45-47) (62). Vitronectin has shown to be more
adhesive than fibronectin (63), another common ligand for integrins, and essential for
7

integrin-dependent cellular attachment. The αVß3 integrin is designated as the vitronectin
receptor (64,65). Integrin αVß3 has been extensively studied in the context of metastasis
(62); such research was initiated by a study that found melanoma cells treated with
antibodies activating this integrin would greatly increase their invasion across the
reconstructed basal membrane (66).
To reiterate, vitronectin has a number of functions in the ECM. In addition to
uPAR and integrin binding, vitronectin binds collagen (12) and may localize plasminogen
and PAI-1 to sites of injury in the vessel wall . Such localization promotes the
proteolytic events necessary for tissue remodeling. Because of these multifunctional
properties of vitronectin in the extracellular matrix, along with interactions of the protein
with uPAR and integrins, vitronectin is a good target for studies on tumor metastasis and
angiogenesis, in that it is inherently involved in these processes.
Vitronectin is also involved in inflammation. The complement cascade is
initiated to prevent and protect against the infiltration of foreign bacteria after the body
suffers an injury. Complement factor C5 is proteolytically modified to C5b (67), which
subsequently reacts with C6 and C7, two other complement proteins. Binding to C7
creates an amphipathic complex that can insert within the plasma membrane (68). This
C5b-7 complex can also react with C8 to form C5b-8 which catalyzes the polymerization
of complement factor C9. This membrane attack complex (MAC) cytolytically acts
through a membrane-penetrating tubule (69). Vitronectin inhibits the cytolytic activity of
the MAC, thus protecting neighboring cells from lysis (13). Vitronectin is also capable
of binding a hydrophobic site on the C5b-7 complex which prevents its insertion in the
plasma membrane (70).
8

Zheng, et al. generated a vitronectin knock-out mouse using gene displacement
(71). Although the knock-out mice are viable, reproduce, and develop normally, studies
with these mice indicate that vitronectin is essential for proper thrombus formation.
Challenging the knock-outs under different pathologies should help to further clarify
functions of vitronectin.

IV. Structure of Vitronectin
Full length human vitronectin has a molecular mass of 72 kDa by analytical
ultracentrifugation (72). In vivo, it can exist in either a full length, single-chain form or a
two-chain cleaved form; cleavage occurs at Arg-379. The residue at position 381 affects
the susceptibility of the protein to cleavage; if threonine rather than methionine is present,
vitronectin is more likely to be cleaved (73). Such action results in a two-chain form of
vitronectin: a 62 kDa heavy chain and a 10 kDa C-terminal light chain. The two chains
are linked via a single disulfide bond. Several different blood proteinases have been
proposed to be responsible for the Arg379—Ala380 cleavage. Recently, however, Seger
and Shaltiel (74) have reported that furin, a serine endoproteinase within the secretory
pathway of hepatocytes, cleaves the bond selectively. This would thus suggest that the
conversion of vitronectin to a two-chain form occurs in the liver (prior to secretion),
rather than in circulation.
Currently, the structure of full-length, native vitronectin has not been determined. This
can be attributed to a number of significant characteristics of vitronectin: 1) its large size
and conformational lability; 2) extensive post-translational modifications (75) leading to
sample heterogeneity; 3) the purification of both the single-chain and double-chain form
9

from human serum which are not effectively separated; 4) the hindrance of site-directed
mutagenic studies due to inefficient recombinant expression systems; and 5) a high
degree of adhesion to surfaces and itself. Recently, however, a prediction by Xu et al.
(76) presents a model for three structural domains of vitronectin (Figure A.3). Sequencestructure alignment and domain fold recognition were performed using the threading
program PROSPECT (Protein Structure Prediction and Evaluation Computer Toolkit).
Vitronectin sequence was “threaded” through two sets of known structure templates and
atomic structures were generated using the MODELLER program. The model
corroborated a published intra-domain disulfide between C137—C161 (77) and predicts
the structure of 1) an N-terminal (somatomedin B) domain; 2) a central region with a
four-bladed β-propeller fold; and 3) a C-terminal heparin-binding domain. In addition to
providing invaluable structural information, these predictions help to support evidence
for the organization of multi-functional vitronectin into these individually folded
domains, which has been tested and described in the literature.

V. Domain Organization
Several studies have been performed to evaluate the multiple functions of
vitronectin and binding to various target ligands. From these investigations, a multidomain protein model has been described. The organization of different domains
provides a broad range of epitopes requisite for the binding of many target ligands.
Indeed, multi-functional proteins are often found composed of independently folded
domains linearly arranged with respect to amino acid, and it appears that vitronectin fits
such a model.
10

Figure A.3: Model for the Three-Dimensional Structure of Vitronectin.
The N-terminal somatomedin B domain (a), central domain with a four-bladed ß-propeller fold (b), and Cterminal heparin-binding domain (c) are shown here in their predicted conformations. The color from the
red to blue shows the sequence order from the N-terminus to the C-terminus. The yellow solid spheres
indicate cysteines. White spheres (a) show the integrin attachment site; red spheres (b) show glycosylation
sites (residues 150 and 223); and thin lines (c) show the heparin-binding site. (d) Linear representation of
the sequence of vitronectin, with blue highlighting corresponding to domains modeled in (a–c), yellow dots
indicating cysteines, red structures representing carbohydrate attachment sites, and the white arrow
pointing to the known site of protease cleavage creating the two-chain form. (e) Docking structure between
the central (blue) and C-terminal (yellow) domains, with cysteines (red lines), presumed heparin-binding
residues (354–363 in white ribbons), sites susceptible to protease (residues 305, 361, 370, 379 and 383 with
light blue spheres), and N-linked glycosylation sites (residues 150 and 223 with green spheres). Predicted
docking of the N-terminal, central and heparin-binding domains (f), and the predicted structure of each
domain separately (g) (76).
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In addition to the computational model, much support for a multi-domain
organization springs from proteolysis experiments where isolated vitronectin fragments
retain their ligand binding function. (Table I summarizes the common vitronectin
digestion products and their ligand binding activity.) Vitronectin is rich is arginines and
lysines, but most of the protein is resistant to cleavage by trypsin-like proteases.
Vitronectin has two sites that are readily accessible to proteolysis: 1) an N-terminal
sequence within residues 44 and 90, and 2) a C-terminal site spanning residues 340-370.
Within the sequence spanning 340-370, vitronectin can be cleaved by plasmin (78,79),
thrombin (78), and mast-cell tryptase (Cynthia B. Peterson and David Johnson,
unpublished observations). Upon prolonged exposure to plasmin, vitronectin is cleaved
near the N-terminus at the K88—G89 bond (80). Trypsin cleaves the protein between R44
and G45 (81). A number of potential elastase cleavage sites also exist in vitronectin, but
elastase only cleaves vitronectin at residues 330 and 383 (79). Synthetic peptides and
monoclonal antibodies have also been integral for the assignment of functional domains
within vitronectin. Additionally, domain organization was determined through
sequencing of human and rabbit cDNAs. The carboxy-terminal of vitronectin shared
sequence homology with another circulatory protein, hemopexin.
The complete open reading frame of vitronectin consists of 8 exons encoding 459
amino acids for the mature protein (exons 2-8), preceded by a 19 amino acid signal
peptide (exon 1). Along its linear sequence, vitronectin is organized into four regions
(Figure A.4) The N-terminal (somatomedin B) domain comprises amino acids 1-44 and
contains eight cysteines which form four disulfide bonds. The second region, a
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Table I: Ligand Binding Activities of Vitronectin Fragments.
Treatment

Fragment

Interaction*

References

Cyanogen Bromide

1-340

+ Cells
+ Heparin
+ PAI-1
- PAI-1
- Cells
- Heparin
- PAI-1
+C5b7
– Cells
+ Heparin
+ PAI-1
- PAI-1
+ C5b7

(82)
(23,82,83)
(83)
(23)
(82)
(82)
(23,82,83)
(84)
(23,82,83)
(13,23,82,83)
(83)
(23)
(13)

+ PAI-1
+ Cells
- Heparin
+ PAI-1
+ Collagen
– Cells
+ Heparin
- PAI-1
+ Collagen

(23)
(82)
(23,82,85)
(23)
(85)
(82)
(23,82,85)
(23)
(85)

51-340

340-381

Formic Acid

1-51
1-217

218-379

Thrombin

1-306

- Heparin
+ PAI-1
- PAI-1

(38,79)
(38)
(79)

Trypsin

1-45

+ PAI-1

(81)

Plasmin

1-361

+ Cells
- Heparin
+ PAI-1
- PAI-1
+ Plasminogen
- uPAR
- Cells
- PAI-1

(80)
(86)
(80)
(78-80,86)
(79,86)
(55)
(80)
(80)

- Heparin
- PAI-1

(79)
(79)

89-361
Elastase

1-330

*A number of ligands were tested for interaction with the described fragments. Positive
interaction is indicated by a “+,” while those fragment-ligands that demonstrated no interaction are
denoted with a “-.”
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N-terminal Domain

Hemopexin Homology
Domain I
Connecting Region

1-44

46-130

Integrin Binding Site
Cleavage Site (RGD)
(44)

131-320

Hemopexin Homology
Domain II

321-459
Heparin Binding Region
(340-379) Cleavage Site
(379)

Figure A.4: The Linear Organization of Vitronectin.
Vitronectin is linearly organized into four domains or regions: an N-terminal (somatomedin B) domain created by
cleavage at residue 44, a connecting region, and two hemopexin domains that share sequence homology to tandem
repeats of the heme-binding protein hemopexin. Yellow circles denote cysteines residues. The integrin recognition
sequence (RGD), the heparin binding site, and a second endogenous cleavage site at residue 379 are also noted.
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connecting region, spans amino acids 45-130 and contains the familiar integrin binding
sequence Arg-Gly-Asp (RGD). The remaining protein consists of seven hemopexin-type
repeats, so named because of their sequence homology to the heme-binding protein
hemopexin. The first four repeats are considered hemopexin homology domain I (aa
131-320) and contain four cysteines. The last three repeats are grouped as hemopexin
homology domain II (aa 321-459), contain 2 cysteines, and house the site of heparin
binding.
It is generally accepted that ligand binding to vitronectin is localized to distinct
domains or linear epitopes. With this acceptance comes the possibility that vitronectin
may interact with more than one ligand simultaneously. Indeed, several examples exist
in the literature. 1) Via interactions with both collagen and heparan sulfate
glycosaminoglycans, vitronectin is incorporated in the ECM (87-89). 2) Matrix
vitronectin binds to both uPAR and integrin receptors on cells. 3) It can bind to PAI-1
and plasminogen (8,90,91), and 4) vitronectin binds glycosaminoglycans concurrently
with the thrombin-antithrombin (TAT) complex (92). Elucidation of ligand epitopes is
important not only for understanding the vitronectin-ligand interaction but also for
appreciating the multi-functional characteristics of this diversified protein.

i. N-terminal (Somatomedin B) Domain
The N-terminal 44 amino acid sequence of vitronectin shares identical sequence
homology to a reportedly naturally occurring circulating “somatomedin B” plasma
protein, present in serum at concentrations of 12-14 µg/ml (93). A separate gene
encoding somatomedin B has yet to be identified, so it is believed that vitronectin is
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cleaved by an (as of yet) unidentified protease to release the somatomedin B (SMB)
domain in vivo (94). The physiological role of somatomedin B has yet to be elucidated
and its name now believed to be a misnomer. It was originally thought to be a member of
the somatomedin/insulin-like growth factor family, but it was later discovered that the
growth-promoting activity of somatomedin B was actually due to trace amounts of
epidermal growth factor in the studies that assigned such activity (95).
Trypsin proteolysis cleaves the N-terminal (somatomedin B) domain from
vitronectin in vitro, and even after prolonged protease digestion, the domain sequence
remains intact. This suggests a tightly folded domain that renders protease susceptible
areas inaccessible. Indeed, 8 of the 14 cysteines in vitronectin lie within this region of
the protein, forming what can be described as an intradomain disulfide “knot” with all 8
cysteines participating in disulfide linkages.
A PAI-1 binding site has been localized to the N-terminal (SMB) domain by
Seiffert, et al. (23). Chemically-derived fragments of vitronectin were shown to compete
with full length vitronectin for PAI-1 binding. After direct binding studies, further
digestion with cyanogen bromide (CNBr) identified the essential binding region as the 6kDa N-terminal (somatomedin B) domain. In addition, monoclonal antibody (mAB) 153,
which recognizes the N-terminal (somatomedin B) region of vitronectin, was used in a
competition study with PAI-1 to further verify PAI-1 binding in this region (96).
Polypeptides of vitronectin were also expressed in E. coli and tested for interaction with
PAI-1. Polypeptides containing residues 1-52 and 1-40 bound to PAI-1, but the 1-30
peptide did not (96). Two additional studies (38,81) also localize PAI-1 binding to the
SMB domain using thrombin-cleaved and trypsin-digested vitronectin fragments.
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Deng et al. (97) generated chimeras between segments of N-terminal (SMB)
domains that bound PAI-1 and segments of the N-terminal domain that did not to
investigate important PAI-1 binding regions. The results of this study indicated that the
essential PAI-1- binding determinant was between residues 12 and 30 on vitronectin.
The importance of proper (SMB) domain folding was also demonstrated in this study.
Alanine scanning mutagenesis created mutants that were screened for ability to bind and
stabilize PAI-1. Results reported that all 8 cysteines and Gly12, Asp22, Leu24, Tyr27,
Tyr28, and Asp34 were necessary to preserve PAI-1 activity.
Additionally, Deng et al. (53) demonstrated that mAB 153 inhibited the binding
of plasminogen activator and urokinase plasminogen activator receptor (uPAR) to
vitronectin, thus also suggesting the binding sites for these ligands in the (SMB) domain.
This study also generated synthetic peptides of vitronectin to confirm the localization of
uPAR binding. It has also been suggested that the thrombin-antithrombin (TAT)
complex binds in this region by a study using antibodies recognizing a 6 kDa CNBr
amino-terminal fragment of vitronectin; the antibodies inhibited the interaction of TAT
with vitronectin (16).

ii. Integrin Binding Sequence
At amino acid positions 45-47 lies the familiar integrin recognition motif of ArgGly-Asp (RGD). The RGD sequence is conserved in a number of other integrin-binding
ECM proteins including fibronectin, fibrinogen, and von Willebrand Factor (62). When
this RGD sequence is selectively mutated (KGD, RAD, RGE) or removed, the ability of
vitronectin to bind cells is lost, thus making this sequence absolutely necessary for
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vitronectin-promoted adhesion and spreading of cells via integrins (98-100). Also, when
the RGD sequence is removed from vitronectin through thrombolytic cleavage, CNBr
hydrolysis, or extended plasmin proteolysis, the cell-binding activity of vitronectin is
weakened (80,82).

iii. Connecting Region
The connecting region of vitronectin extends from amino acids 45-130 and
although it contains no cysteines, it does include sites for a number of modifications.
Tyrosine residues 56 and 59 are modified by sulfation (101), and asparagine residue 67 is
involved in N-linked glycosylation (94). Additionally, vitronectin has been identified as
a substrate for transglutaminase and factor XIIIA in vitro, with glutamine residues 73, 84,
86, and 93 believed to be the primary substrates for transaminoglutaminate reactions (77).
Transglutamination stimulates the formation of higher order vitronectin complexes that
cannot be dissociated by either SDS or reducing agents. It is not known whether
multimerization of vitronectin in vivo is mediated by transaminoglutaminase.
Several ligands are proposed to have binding sites within the connecting region,
including a second binding site for PAI-1. Studies with Staphylococcus aureus protease
V8-cleaved vitronectin identified an inhibitory fragment in this region (102). In the same
study, a synthetic peptide corresponding to residues 115-121 inhibited PAI-1 binding to
vitronectin by 50%. This same peptide also stabilized PAI-1 activity in kinetic assays.
A phage display synthetic peptide competed against immobilized vitronectin for
heparin binding, suggesting the localization of a heparin binding site within the
connecting region (103). Ishikawa-Sakurai et al. have shown that formic acid-hydrolyzed
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vitronectin polypeptides containing the connecting regions demonstrate affinity for
collagen (85). The use of mAB in competition experiments also supports a collagen
binding site within this region (104).

iv. Hemopexin Repeats
The remaining portion of vitronectin (amino acids 131-459) consists of seven
“hemopexin repeats” organized into two domains—hemopexin homology domain I and
hemopexin homology domain II (HPD I and II). The individual domains of hemopexin
are comprised of four tandem repeats. The structure of hemopexin is a 4-bladed ßpropeller fold, with each repeat corresponding to a blade of the propeller. Vitronectin
contains seven repeats, one less than the eight repeats requisite for two complete
hemopexin domains (105). Like the N-terminal (somatomedin B) domain and the
connecting region, the hemopexin homology repeats of vitronectin are highly resistant to
proteolytic cleavage. Six cysteines are contained in this portion of the protein, two of
which are reduced and buried (72). Two additional N-linked sites of glycosylation are
found at asparagine residues 150 and 223 (94).
HPD I extends from residues 131-320 and contains the first four tandem repeats
representative of a complete hemopexin structure. HPD II comprises amino acids 321459 and contains the remaining three repeats which could result in an incomplete threedimensional fold in regards to hemopexin. HPD II houses the important heparin binding
site, discussed further below.
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v. Heparin Binding Sequence
A cluster of basic amino acids (residues 345-379) lies within the second
hemopexin homology domain and houses the apparent binding site of heparin. Within
this region, two motifs are identified that correspond to the heparin-binding consensus
sequences derived from (other) heparin-binding proteins (106). Additionally, serine 378
within this region is phosphorylated in vivo; in vitro phosphorylation has been
demonstrated by protein kinase A (107-111). Mentioned previously, vitronectin
circulates in both a double and single chain form resulting from proteolytic cleavage
between arginine 379 and alanine 380 (112). The charged heparin-binding sequence and
the residues flanking the sequence exhibit increased susceptibility to proteolytic cleavage
in vitro, which is in contrast to a majority of the other tightly folded regions of
vitronectin.
In addition to the high degree of similarity between this region and other
sequences in known heparin-binding proteins, a number of studies have been performed
on this region to further support a heparin binding site. CNBr digestion yields a product
that competes with full-length vitronectin for heparin binding and inhibits the
anticoagulant acitivity of heparin (82). Studies reported by Gibson et al. (113)
demonstrate that heparin binding is significantly reduced upon the incorporation of a
arginine-reactive probed. This probe was later localized to a CNBr fragment
corresponding to residues 341-380. Further work by this group with recombinant
polypeptides of the 129 C-terminal amino acids shows that heparin binding affinity of
this polypeptide is comparable to that of full length vitronectin (114), thus suggesting that
this region of vitronectin is responsible for heparin binding. Synthetic peptides and
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mABs mapping to the heparin binding region inhibit the binding of heparin to this region
of vitronectin (86). Plasmin proteolysis within this region hinders the ability of the
resultant vitronectin to bind heparin (79,86). In addition, removal of sequences between
residues 306-370 and 331-383 (via the addition of thrombin and elastase) also
demonstrates a loss of heparin-binding activity (79).
A number of other target ligands of vitronectin have been localized to the heparin
binding region including PAI-1 (78,83,115,116), plasminogen (83), uPAR (53),
complement complex (69,117), collagen (85,87), and the thrombin-antithrombin (TAT)
(118). Additionally, a number of microorganisms may bind vitronectin at the heparinbinding sequence (119-121). TAT, uPAR, complement complex, and collagen binding
regions were elucidated using either synthetic peptides or CNBr cleavage products. In
these studies, binding of the various ligands to full-length vitronectin was inhibited by the
peptide or cleavage product.
More extensive experimentation has been performed to localize the binding sites
for plasminogen and PAI-1 to this region. A plasmin cleavage product containing
vitronectin residues 1-361 retains plasminogen-binding activity (79,86). The
plasminogen activity was disrupted by treatment of the peptide with carboxypeptidase
which suggests the C-terminal of the fragment is involved in the interaction with
plasminogen. Kost et al. used a number of overlapping synthetic peptides derived from
the heparin-binding region of vitronectin to localize the plasminogen binding site to
residues 340-348 (86). Further evidence by Preissner supports this localization;
Stapholococcus V8 protease-cleaved fragments and cathepsin D fragments bound both
heparin and plasminogen in ligand-blotting assays (91)
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In other studies by Preissner, it was demonstrated that active or latent PAI-1 binds
to immobilized synthetic peptides corresponding to the heparin-binding region. These
peptides also inhibited vitronectin binding to PAI-1 in microtiter plates (116). Kost et al.
used mABs and competitive assays to localize PAI-1 binding to this region of vitronectin
(86). The suggestion that PAI-1 and heparin share a binding site on vitronectin was
further supported by three studies using plasmin proteolyzed vitronectin (78,80,115).
Plasmin cleaves vitronectin between residues R361 and S362. Vitronectin cleaved with
plasmin was unable to bind heparin or PAI-1. While intact vitronectin formed a PAI-IVN complex that could be co-immunoprecipitated using antibodies to PAI-1, elastaseand thrombin-cleaved vitronectin did not form such a complex with PAI-1, not surprising
because these proteases excise the heparin-binding domain (108). Vitronectin peptides
were also generated by Preissner et al. through CNBr hydrolysis (83), and these peptides
demonstrated that both PAI-1 and heparin bind the same 9 kDa fragment that includes the
carboxy-terminal of vitronectin. However, Gibson et al (113) provide evidence through
the use of fluorescent probes that binding determinants for PAI-1 and heparin are not
shared.

VI. Considerations
The evidence suggests almost undoubtedly that vitronectin is organized to support
multiple domains; multiple domains facilitate the accommodation of several ligand
binding sites, many of which have been localized and described in the literature. Upon
examination of vitronectin activity during different interactions and the epitopes reported,
a number of discrepancies can be noted. How are these discrepancies explained?
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i. Considerations of the Protein
Perhaps the most obvious thing to consider is that there may be more than one
binding site on vitronectin for a particular ligand. For example, a possible resolution for
the conflicting information concerning PAI-1 binding sites has been suggested by the
description of two binding regions on vitronectin—one exhibiting high-affinity binding,
the other demonstrating lower affinity. The well-defined high affinity binding site is
located in the SMB domain and the second binding region is suggested at the C-terminal.
Indeed, a model has emerged that describes PAI-1 binding first to the low affinity
binding site at the C-terminal which induces a conformational change in the SMB that
unmasks the high-affinity binding site. PAI-1/vitronectin complex (either the 1:1 or 2:1
form) can associate into high order oligomers via the self-association of the vitronectin
component(s) (122,123).
A second consideration is the conformational lability of vitronectin. The protein
can display differential binding activities depending on a specific fold. This fold-specific
binding was suggested to be responsible for observations concerning the interaction of
vitronectin with heparin. The heparin-binding site was first proposed to be buried within
the native protein. A model prevailed suggesting that upon denaturation, the cryptic
recognition site was exposed and heparin was able to bind (124).
However, Zhuang et al. found that denaturation of vitronectin is accompanied by
self association into the multimeric form (125). A later study determined that heparin
binding to both monomeric (native) and multimeric (denatured, renatured) vitronectin is
the same (126). It is thus concluded that the heparin binding site is fully exposed and not
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buried within the native fold, and a new model was proposed. In this model by Peterson
(Figure A.5), the heparin binding site is fully exposed on the surface and does bind
heparin. When vitronectin is refolded, it passes through a partially folded intermediate
state that has a propensity to aggregate which leads to the formation of multimers.
Observed enhanced heparin binding can be attributed to the alignment of multiple heparin
binding sites in the multimeric vitronectin, not the exposition of an encrypted site on a
monomer. This example also emphasizes the importance of monomer/multimer
considerations when studying ligand interactions. Enhanced interaction may be due to a
“Velcro-effect” rather than a change in fold.
Yet another consideration is enzymatic modification. Studies indicate vitronectin
is susceptible to intracellular and extracellular proteolysis. Proteases like plasmin and
thrombin, which are highly concentrated at injury sites, may cleave vitronectin and affect
PAI-1 and heparin binding. In addition, vitronectin contains two sites of endogenous
proteolytic cleavage, one at residue 44 that releases the SMB domain and one at 379 that
is responsible for the two chain form of vitronectin. Endogenous removal of the SMB
domain demonstrates decreased affinity for PAI-1 (81); it must be considered that other
ligand interactions may be affected by endogenous cleavage at these sites.
Already mentioned are the post-translational modifications of vitronectin, another
consideration. (Figure A.6 shows sites of post-translational modifications as well as a
summary of proposed ligand binding sites within the domain structure of the protein.)
Protein kinase A phosphorylates vitronectin within the heparin-binding sequence, both in
vitro and in vivo. This phosphorylated form of vitronectin may demonstrate altered
binding activities towards the ligands that interact with the arginine-rich C-terminal
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Figure A.5: Multimerization Model.
This model by Peterson suggests that plasma vitronectin is folded with the heparin-binding site exposed
on the surface of the protein. During refolding, vitronectin passes through a partially folded intermediate
that has a propensity to aggregate. Multimeric vitronectin results that has heparin-binding sites aligned
on the surface of the molecule, providing multivalent interaction with heparin.
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Figure A.6: Post-translational Modifications and Proposed Ligand Binding Sites Within the
Domain Organization of Vitronectin.
As previously described, vitronectin is organized into four domains. This figure illustrates the sites of
post-translational modifications within each domain. Also, a number of ligand binding sites have been
proposed in the literature for many of the ligands with which vitronectin interacts. Some proposed
ligand binding regions are represented here. Cysteine residues (C) are noted, as well the integrin
recognition sequence (RGD) and the heparin binding site.
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sequence of vitronectin (108,109,115,127). Other modifications could affect ligand
binding in yet undetermined ways.
In summary, conformational lability, multimerization effects, enzymatic
cleavages, and post-translational modifications can all contribute to discrepancies in data
if not taken into consideration. A burden is placed on the researcher to select appropriate
methods and preparations that will produce results that can be confidently interpreted.

ii. Considerations of Methods
A number of methods were used to localize ligand binding sites to the different
domains of vitronectin. Discrepancies for binding determinants have been encountered,
especially concerning the binding sites for PAI-1. In the literature, PAI-I has been
mapped to three different regions of vitronectin: the somatomedin B domain (23,81), the
heparin binding region (86), and residues 115-121 in the connecting region (102).
Closer examination of the methods employed by different groups reveal possible
explanations for separate sites for PAI-1 binding and a number of general concerns for
techniques commonly used to map ligand binding sites.
Many of the binding sites were determined using fragments of vitronectin
generated through chemical and proteolytic cleavage, as well as synthetic peptides.
These methods are susceptible to experimental artifact, and for many experiments, high
concentrations of the fragments were required to retain function. One must keep in mind
that fragments of proteins will not necessarily mimic in vivo interactions (full-length
proteins will not necessarily, either).
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Studies with monoclonal antibodies can present problems as well. Often, if a
particular monoclonal is found to inhibit or compete for ligand binding to a region of
vitronectin, that region of vitronectin is assumed to be a site of binding. Such
assumptions must be made cautiously. In characterization of the heparin binding region,
the monoclonal antibody 8E6, which supposedly mapped to the heparin binding site, was
used to support the “encrypted site” model previously mentioned. It was later shown by
Seiffert that 8E6 recognized a different epitope on vitronectin (128). This antibody
apparently binds at the N-terminal and disrupts structure at the C-terminus, which
disrupts heparin binding. This could be the case for other monoclonals. Other concerns
include inconsistent preparation of the proteins involved in the assays and usage of
different forms of the ligand, including PAI-1 which exists in both an active and latent
form.

VII. Rationale
Much work has been done to localize PAI-1 binding to vitronectin and to
understand the interaction between the protein and heparin. But another important ligand
that binds vitronectin is the thrombin-antithrombin (TAT) complex. Complex interaction
with vitronectin has not been characterized extensively, with the regions (and residues)
on vitronectin involved in binding not conclusively identified. Using overlapping
recombinantly expressed polypeptides of vitronectin, the Far Western approach has been
employed to localize the binding of TAT to vitronectin. Such localization will help to
further describe the vitronectin-TAT interaction and provide impetus for further study.
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These polypeptides are further used to epitope map a number of murine monoclonal
antibodies to vitronectin our laboratory has recently acquired.
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Part B
Localization of the Thrombin-Antithrombin Binding Site(s)
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I. Introduction
As previously mentioned, we know with confidence that vitronectin binds many
ligands. A number of approaches have been used to determine the number of binding
sites for each ligand and the region(s) of vitronectin involved in the interaction(s). The
approach taken in this project involves the expression of bacterial recombinant
polypeptides of vitronectin. The polypeptides are tested for interaction with TAT using a
Far Western approach.
The Far Western technique (sometimes referred to as a “West-Western”) is a
derivation of the traditional antigen-antibody interaction of the Western blot. Far
Westerns are commonly used to screen cDNA libraries and/or to study protein-protein
interactions. Here, the Far Western technique involves the incubation of a second protein
of interest with an immobilized protein (electroblotted onto nitrocellulose). Interaction is
visualized by detection of an antibody to the second protein.
The use of the Far Western technique with recombinant fragments to localize
ligand binding sites is unique to the body of vitronectin research. The first target ligand,
which is the focus of this project, is the thrombin-antithrombin complex. Thrombin,
antithrombin, the complex, and interactions with vitronectin will be reviewed in the next
sections.

i Thrombin
Thrombin has many diverse functions in the body, it is the ultimate activation
product of the coagulation cascade. Upon injury, the blood coagulation cascade works
through a series of enzymatic cleavages that activate sequential “clotting factors” that can
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in turn cleave the next factor until finally soluble fibrinogen is cleaved by thrombin into
insoluble fibrin. Thrombin serves as a regulator of the coagulation process through both
stimulatory and inhibitory feedback mechanisms. It has thus been a popular target for
anticoagulant drug therapy (129).
Thrombin is a serine protease that recognizes particular sequences and catalyzes
the hydrolysis of arginine-glycine peptide bonds. After the peptide cleavage of
fibrinogen, fibrin monomers are left with a specific surface charge pattern that promotes
their aggregation, and this clustering together forms a fibrous blood clot (130,131).
Thrombin has also been shown to trigger platelet aggregation and catalyze the activation
of other blood clotting factors V, VIII, and XIII (132).
Human blood plasma contains approximately 40-50 mg/L of thrombin, and such a
concentration is required for proper blood clotting to occur efficiently. Thrombin is
activated by the cleavage of its zymogen prothrombin by factor Xa and factor Va.
Thrombin’s activity is controlled by negative regulators antithrombin III and hirudin,
both of which function by binding to thrombin’s active site.
Thrombin shares structural homology to serine proteases trypsin and
chymotrypsin. Thrombin is a glycoprotein formed by two disulfide-linked peptide chains
of 36 and 259 amino acids. Three sites of interaction have been identified on the protein,
the first of which is the negatively charged catalytic site that confers thrombin’s serine
protease activity and contains the familiar catalytic triad. On thrombin, these residues
include histidine 43, aspartic acid 99, and serine 205 (133).
The other two sites of interaction are positively charged and named exosite 1 and
exosite 2. Exosite 1 borders the catalytic site and binds substrate (fibrinogen or thrombin
32

receptor). On the enzyme surface, exosite 2 is located proximal to exosite 1 and
bindsinhibitor antithrombin III responsible for thrombin’s inactivation (134-136).
Exosite 1 also binds Factor V and Factor VIII, while exosite 2 contains the binding site
for heparin and thought to be involved in interaction with Factor V and Factor VIII
(137,138). Thrombin also interacts with fibrin at either exosite 1 or exosite 2 in a manner
dependent on whether heparin is present or absent, and then the concentration of heparin
in the environment if heparin is indeed present. But in any binding event, thrombin
remains active due to fibrin binding at a site distinct from the catalytic site on thrombin
(139-141).
Fibrinolysis is the process of clot dissolution, thus thrombin is usually thought of
as an inhibitor of fibrinolysis. Interestingly, however, thrombin also demonstrates
stimulatory effects on the process. First, thrombin is a chemoattractant for neutrophils;
neutrophils have demonstrated a role in fibrin clot degradation (142). Second, thrombin
releases plasminogen activators from endothelial cells (143). These plasminogen
activators generate plasmin, a key initiator of fibrinolysis and inactivator of prothrombin.
Thrombin’s capacity to both inhibit and enhance fibrinolysis demonstrates yet again its
vital role in hemostasis and the fine balance between clot formation and clot dissolution.
Disruption of this fine balance leads to either excessive hemorrhage or excessive
coagulation, conditions that can be potentially fatal.
As previously mentioned, thrombin is a chemoattractant for neutrophils and
monocytes. Due to this association, thrombin is also involved in inflammation. At the
sites of an injury, thrombin concentrates, inducing these cells to gather and carry out their
phagocytic role to protect against potential bacterial infection (144,145).
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Human α-thrombin is composed of two disulfide-linked chains—a 36 amino acid
long A chain and a 259 amino acid long B chain (146). ß and γ-thrombin result from the
limited trypsin proteolysis of α-thrombin’s B chain (147). ß-thrombin is formed by a
cleavage at either Arg75—Tyr76 and/or Arg77—Asp78 whereas γ-thrombin has an
additional cleavage at Lys149—Gly150 (148). γ-thromin consists of three polypeptide
segments that are non-covalently associated (149). Each polypeptide contains one of the
catalytic triad residues: Asp-99 is on the A-B3 chain, His-43 is on the B1 chain, and Ser205 is on the B4 chain (150). Significantly, when α-thrombin is cleaved to create γthrombin, clotting activity is either lost or very low, although enzyme activity is retained
(149,150). This is explained by disruption of the active site and also an upset of the
fibrin(ogen) recognition site on γ-thrombin (151).
γ-thrombin does bind to antithrombin, but at a reportedly lower rate compared to
α-thrombin (152). Electron spin resonance studies indicate that contained within the
active site of γ-thrombin is a hydrophobic region not present in α-thrombin (153). This
altered active site of γ-thrombin may be responsible for findings that revealed a much
tighter binding of γ-thrombin to vitronectin compared to α-thrombin. Additionally, it was
suggested that the α-thrombin component of thrombin-antithrombin was responsible for
interaction with vitronectin, probably through a region exposed on γ-thrombin (11).

ii. Antithrombin
Antithrombin is a 432 amino acid glycoprotein that plays an important role in the
regulation of blood clotting (154). In plasma, antithrombin is the major inhibitor of
coagulation proteases such as thrombin, Factor Xa, and Factor IXa (155-158).
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Specifically, antithrombin is a serine protease inhibitor (serpin) (159). Antithrombin
deficiencies disrupt hemostasis and can lead to venous thromboses, thus demonstrating
the important role it plays in maintaining the fine balance between abnormal clotting
extremes.
Antithrombin shares structural homology with α1-proteinase inhibitor, PAI-1,
heparin cofactor II, and α1-antichymotrypsin--other protease inhibitors (35). It contains
three disulfide bonds and four sites of glycosylation (154). Two X-ray structures of
antithrombin have been acquired and studied—an intact form and an inactive, cleaved
form (160,161). Intact antithrombin possesses two prominent features: 1) a five-stranded
ß-sheet, the A sheet and 2) a large exposed loop containing the reactive bond (Arg 393—
Ser-394). Inactive antithrombin is cleaved near the reactive bond, and the N-terminal
portion of the reactive loop is inserted as a middle strand in the A ß-sheet.
One of antithrombin’s most physiologically critical targets is thrombin.
Antithrombin binds thrombin in a 1:1 stoichiometric ratio whereby thrombin is
inactivated in a two-step process. After the formation of an initial “encounter” complex,
a conformational change occurs to form a stable serpin-enzyme pair (162-167). Enzyme
inactivation is initiated upon recognition by the enzyme of antithrombin’s reactive bond
(168-170). Antithrombin residue Arg-393 is essential for this recognition (171-173). On
thrombin, the serine of the active site (174) and Trp-60 (175,176) are required for proper
interaction with antithrombin. It is believed that thrombin attacks the reactive bond of
the fully exposed loop as in regular substrate binding. When this happens, the loop with
thrombin bound folds into the A sheet of antithrombin and this insertion traps the enzyme
in a stable complex with inhibitor whereby the enzyme is inactivated (174,177-180).
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Heparin is a strongly negatively charged glycosaminoglycan that greatly
accelerates the rate of inhibition of thrombin (and other clotting proteases) by
antithrombin. Indeed, the thrombin-antithrombin pairing rate increases 2000-4000 fold in
the presence of optimal concentrations of heparin (181-184). Heparin confers its effect
by first binding to antithrombin (182,185). Positively charged residues on antithrombin
recognize a specific pentasaccharide sequence of heparin (186-190), and upon binding, a
conformational change takes place in antithrombin (Figure B.1). It is then believed that
thrombin non-specifically binds the same heparin chain at any number of sites along the
polysaccharide (183,191). Thrombin travels down the chain and meets the inhibitor,
where the two interact. Serpin-enzyme complex formation results in a greatly diminished
affinity for heparin (185,192). Thus, heparin quickly dissociates, leaving it free to bind
another antithrombin molecule.

iii. Interactions of the Complex with Vitronectin
Vitronectin interacts with the thrombin-antithrombin (TAT) pair to form a ternary
complex (17,20). In fact, most TAT found in human serum is complexed with
vitronectin (31,118). The association of vitronectin with TAT is important for a number
of reasons. 1) Vitronectin confers its heparin-binding (15) and cell-binding (193)
properties to the TAT pair when the two components are bound. 2) Studies indicate a
conformational change in plasma vitronectin upon binding of TAT (15). 3) It has been
speculated that ternary complex formation is the primary mechanism by which
circulating vitronectin is translocated to the extravascular space (1). And 4) It has been
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Figure B.1: Vitronectin Association with TAT and Heparin.
This schematic represents the heparin-enhanced association of thrombin with its
inhibitor antithrombin. Vitronectin binds not only the complex, but the molecule that
facilitates complex formation. It is believed that once vitronectin binds TAT, the
ternary complex is cleared from circulation.
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suggested that vitronectin binding to TAT is largely responsible for the clearance of the
complex from circulation (92,194,195).
Previous work from this laboratory has contributed significantly to the
understanding of the interaction between vitronectin and TAT. These studies have shown
that the thrombin component of TAT is responsible for vitronectin binding, in that
thrombin alone can bind vitronectin, but antithrombin is only detected bound to
vitronectin when it is complexed with thrombin. Additionally, high performance liquid
chromatography (HPLC) experiments demonstrated that VN-T-AT complexes lead to
vitronectin multimerization over time.
The nature of the interaction between vitronectin and TAT has been reported to be
a covalent interaction formed by a disulfide bond (11,15,112), catalyzed by protein
disulfide isomerase (PDI) (196). Neither thrombin nor antithrombin has free sulfhydryl
groups, thus a thiol-disulfide exchange is suggested, with the thiol(s) being contributed
by vitronectin (112). In contrast, additional work from this laboratory reports evidence
that the interaction is not disulfide mediated, but is rather an ionic interaction; in the
presence of iodoacetamide, ELISA experiments demonstrated that VN-T-AT complexes
were not affected.
Other subjects of speculation and study concerning the vitronectin-TAT
interaction are 1) how many binding sites does vitronectin contain for the thrombinantithrombin pair and 2) what regions of the protein are involved in the interaction with
TAT?

This laboratory has demonstrated that the binding site for the thrombin-

anithrombin complex is separate from the PAI-1 binding site. It has also been suggested
through monoclonal antibody experimentation that the amino portion of vitronectin is
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involved in ternary complex formation (16), although the interaction is proposed to be
disulfide-mediated, which our laboratory disputes. Early reports speculated that the
heparin binding region of vitronectin could be a potential site for the vitronectin-TAT
interaction (124,181). The focus of the research presented here is to use recombinantly

expressed fragments of vitronectin to localize the binding region(s) for thrombinantithrombin. The interaction will be detected using a Far Western technique.

II. Experimental Procedures
i. Proteins, Antibodies, and Protease Inhibitors
The proteins, antibodies, and protease inhibitors used throughout this study were
obtained as follows. Native, monomeric vitronectin was purified from human blood
plasma using a modified protocol of the method developed by Dahlback and Podack
(112). Human α-thrombin was purchased from Haematologic Technologies, Inc. and
human antithrombin III was obtained from the American Red Cross (manufactured by
Baxter Healthcare Corporation). Polyclonal antibodies to human α-thrombin and human
antithrombin III were also purchased from Haematologic Technologies, Inc. Monoclonal
anti-polyhistidine clone his-1 (peroxidase conjugated) was purchased from Sigma. HRPconjugated secondary antibodies were purchased from Vector labs (anti-mouse and antigoat) and Santa Cruz Biotechnology (anti-sheep). All protein standards were
Kaleidoscope protein or polypeptide standards purchased from Bio-Rad. Protease
inhibitors Pepstatin A, Leupeptin, and Pefabloc SC were purchased from Roche.
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ii. Transformation into Expression Cells
cDNAs encoding eight overlapping polypeptides of vitronectin 100 amino acids
in length (aa 1-100, 51-150, 101-200, 151-250, 201-300, 251-350, 301-400, and 351-459)
were obtained from D. Seiffert (DuPont Merck Research Laboratories). Figure B.2
demonstrates the domains of vitronectin each polypeptide spans. These were cloned into
the multiple cloning site of pET-15b (Novagen) which carries an N-terminal His-Tag
sequence. The recombinant plasmids were transformed into BL21DE3pLysS E. coli
(Novagen) according to company protocol.

iii. Directional Cloning of aa 251-350 and 301-400
It was determined from Christine Schar’s previous work that the original DNA for
polypeptide 251-350 (obtained from D. Seiffert) contained mutations at positions ****
Christine worked to correct the sequence and cloned the corrected gene into the yeast
vector pAS2-1 (Clonetech) to pursue yeast two-hybrid studies.
For the research presented here, the 251-350 polypeptide cDNA was cloned back
into pET15b. pAS2-1/251-350 was transformed into DH5α E. coli. The recombinant
plasmid was purified using a midiprep kit (Qiagen). The 251-350 cDNA was excised
using the restriction enzymes BamHI and NdeI (part of the multiple cloning sites in both
plasmids of interest), available from Fisher Scientific. 251-350 cDNA was purified from
1.5% agarose gel electrophoresis using Qiagen’s QiaQuick Gel Extraction Kit. pET15b
was also purified from 1.0% agarose gel electrophoresis using this kit. A ligation
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Figure B.2: Linear Organization and Corresponding 100 Amino Acid Polypeptides.
Vitronectin is (linearly) organized into 4 regions. The 14 cysteines are noted, as is the familiar integrin binding recognition
sequence (RGD) at the end of the somatomedin B region, and the heparin-binding site in hemopexin domain II. Overlapping
polypeptides 100 amino acids in length were engineered and cloned into the pET expression system. They are shown here to
give a general idea as to which region(s) each encompasses.
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reaction was performed using Invitrogen’s T4 DNA ligase according to company
protocol. The reaction was transformed into DH5α cells and plated on LB/amp.
Colonies were grown overnight in 2 ml TB/amp, midiprepped (Qiagen), and a double
digest was performed to confirm insert. Upon confirmation of insert (visualization of
~300 bp band), plasmid/insert was transformed into BL21(DE3)pLysS E. coli according
to company protocol.
Upon DNA sequence analysis of the 301-400 recombinant, it was determined that
the lac operator harbored a mutation. To correct the problem and obtain a functional
operator, the 301-400 cDNA was excised from the mutated plasmid again using the
restriction enzymes BamHI and NdeI. 301-400 was purified from 1.5% agarose gel
electophoresis using Qiagen’s QiaQuick Gel Extraction Kit. The gene was ligated into
the previously purified pET15b using Invitrogen’s T4 DNA ligase according to company
protocol and plated as described above. Confirmation of insert was visualized using
agarose gel electrophoresis and DNA sequence analysis demonstrated a corrected lac
operator.

iv. Small-scale Inductions
Isolated colonies from the previously mentioned transformations were selected for
overnight growth (37oC with shaking) in 2.0 ml of Terrific broth (TB available from
Gibco) containing ampicillin (50µg/ml) and chloramphenicol (34µg/ml). Duplicate
cultures of each colony were prepared and grown to mid-log phase and protein
expression was induced in one of the duplicate cultures with 1.0mM IPTG (Sigma) and
grown for another 4 hours. All cultures were harvested using centrifugation (13,000 rpm
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5 min.) and the supernatant was decanted. Cells were resuspended in 50 µl 2X sample
loading dye, boiled, and analyzed using 15% SDS PAGE. Expression was assayed by
immunoblotting to nitrocellulose at 20V for 20 minutes. Membranes were blocked for 1
hour in 10% dry milk/PBS. After washing, membranes were incubated with an antipolyhistidine antibody (peroxidase conjugated) at a dilution of 1:2000. Expression was
detected upon addition of substrate (12µl H202, 30ml PBS, 6 ml 4-chloro-1-naphthol).

v. Large-scale Inductions/expression
2.0 L of enriched media (47.0 g/L TB, 5.0 g/L YNB (Difco), 4.0 ml/L glycerol,
50µg/ml amp, 34µg/ml chlor, pH 7.2) was prepared and inoculated with 100 ml of ~2.5
hour culture (TB/amp/chlor). Cells were allowed to grow with shaking at 37oC till OD600
indicated log phase. Protein expression was induced with 1.0 mM IPTG (Sigma) and
cells allowed to grow for another 8-12 hours. Cells were harvested by centrifugation
(10,000 rpm at 4oC in Beckman JA-10 rotor for 30 minutes) and stored in -20oC freezer
until purification.

vi. Metal-chelating Affinity Chromatography
2.0 L cells were resuspended in 160 ml resuspension buffer (5mM imidazole,
40mM Tris-HCl, 500mM NaCl, leupeptin, Pefabloc, Pepstatin A, pH 7.9). Cells were
lysed using sonication. Sonication product was separated using centrifugation (10,000
rpm in Beckman JA-10 for 30 min., 4oC). Supernatant was poured off and reserved; 30
µl of the supernatant was analyzed by 15% SDS PAGE. If the polypeptide was contained
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in the pellet portion, 60 ml of solubilization buffer (5mM imidazole, 40mM Tris-HCl,
500mM NaCl, 6.0 M urea, protease inhibitor cocktail, pH 7.9) was added to the
sonication pellet and the pellet resuspended. Cellular debris was separated from the
solubilized pellet by centrifugation (10,000 rpm in Beckman JA-10 rotor, 40 min., 4oC)
and the supernatant reserved.
Soluble or urea-solubilized polypeptide sample was loaded on an equilibrated
Chelating Sepharose® Affinity column (Pharmacia) charged with 100mM NiSO4 at a
flow rate of 1.0 ml/min and 3.0 ml fractions were collected. Wash buffer (16 mM
imidazole) was passed over the column till A280 readings were ~0.00. Protein was stepwise eluted with 75 mM, 150 mM, and 300 mM imidazole buffer. Fractions were
analyzed on 15% SDS-PAGE and Western blotted with fractions containing polypeptide
detected using an anti-polyhistidine antibody. Protein concentrations were determined
using the Bradford Assay (reagents available from Bio-Rad). Polypeptide 101-200
fractions were concentrated using an Amicon (10,000 molecular weight cut-off) 4.0 ml
centrifuge concentrator. 3.0 ml of sample was loaded and centrifuged 30 minutes in a
swinging bucket centrifuge (4000 rpm, 4oC).

vii. Far Western Technique
1. Full-length Vitronectin
Either 3 or 5 µg native vitronectin in PBS was loaded on a 10 % gel and SDSPAGE was performed. Protein in the gel was transferred to nitrocellulose at 20V for 20
minutes, blocked for 1 hour in 10% dry milk/PBS, and then incubated overnight with
shaking at 4oC with 100 µl thrombin-antithrombin complex in 30 ml PBS solution
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(complex prepared by incubating 400 ug/ml thrombin with 1.5 mg/ml antithrombin for
one hour to form a stable complex). After washing with PBS/0.1% Tween, the
membrane was divided and incubated with shaking for one hour at room temperature
with an antibody raised against either thrombin or antithrombin. Each membrane was
washed again with PBS/Tween and peroxidase-conjugated secondary antibodies
(thrombin -- anti-sheep; antithrombin -- anti-goat) were allowed to bind for one hour with
shaking at room temperature. The membrane was developed upon addition of substrate.

2. Polypeptide Fragments of Vitronectin
Approximately 20µg of each pure polypeptide was loaded into 15% SDS-PAGE.
Two different Western blot protocols were employed with the polypeptides involving two
different transfers. In some experiments, polypeptides were transferred to nitrocellulose
at 20V for 20 minutes using a BioRad Semi-dry Blotter and the same protocol was
followed as for the native, full-length vitronectin. Alternatively, some polypeptide gels
were transferred to Immobilon™ (Millipore) at 24V for 30 minutes in a submerged gel
transfer apparatus. The membranes were blocked for 1 hour in 5% dry milk in TBS/0.1%
Tween. The membranes were then incubated overnight at 4oC with the thrombinantithrombin complex (prepared as described above) in TBS/Tween. The membrane was
washed 3X for 10 minutes in TBS/Tween. Membranes were incubated with either an
anti-thrombin or anti-antithrombin antibody for 40 minutes in 2.5% dry milk in
TBS/Tween. Again, the membranes were washed and appropriate peroxidase conjugated
secondary antibodies were allowed to bind for 40 minutes. The membranes were washed
as described and then bathed in a 1:1 solution of SuperSignal® Chemiluminescent
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Substrate ULTRA Stable Peroxide Solution and Chemiluminescent Luminol/Enhancer
Solution (Pierce) for 1 minute. The membranes were exposed on a film sheet for 5
minutes and developed in the dark room.

III. Results
i. Cloning of 251-350 and 301-400
The cDNA encoding polypeptide 251-350 obtained by our laboratory included
mutations that were corrected by another member of our lab and cloned into a yeast
vector. For expression in the pET system, it was essential that the corrected cDNA
sequence be cloned into pET15b. Figure B.3a is a schematic representing the cloning
procedure. The cDNA was excised by a double digest with BamHI/NdeI, which would
also linearize the plasmid. After successful purification of cDNA 251-350 and pET15b
from an agarose gel, T4 DNA ligase was used to ligate the cDNA into the plasmid and
the reaction was plated. Colonies were analyzed by agarose gel electrophoresis and as is
obvious from the gel picture in Figure B.3b, a successful clone resulted.
The cDNA encoding polypeptide 301-400 was originally in pET15b and the
cDNA was shown to be correct by DNA sequence analysis, yet no polypeptide was
expressed when transformed into BL21(DE3)pLysS cells. Upon sequence analysis of the
promoter region, a mutation was found in the lac operator, which was believed to be the
culprit of no expression. Thus the cDNA was excised and purified from the deficient
plasmid and cloned in a similar procedure as 251-350 into the already successfully
purified pET15b. After several attempts, a successful ligation was obtained, seen in
Figure B.4, and sequence analysis confirmed a correct sequence in the promoter region.
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Figure B.3: Cloning of 251-350.
a. Schematice representing the cloning strategy for 251-350. cDNA was excised from the yeast plasmid
pAS2-1 using restriction ezymes BamHI and NdeI. It ws then ligated into the expression plasmid pET15b
which contains an inducible T7 promoter and confers ampicillin resistance.
b. A 1.5% agarose gel picture of double digested recombinant plasmid. After the cDNA was transformed into
DH5α cells, the recombinant was purified, double-digested with BamHI/NdeI and analyzed by
electrophoresis. The 251-350 cDNA is shown at ~300bp.
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pET15b
4.7 kb

+
301-400
~300bp

Figure B.4: Agarose Gel Picture of 301-400.
cDNA coding for polypeptide 301-400 was cloned into pET15b, double
digested with BamHI/NdeI and analyzed by agarose gel electorphoresis.
The 301-400 cDNA does appear around bp 300, but subsequent attempts
to express this polypeptide by transformation into BL21DE3pLysS cells
did not prove successful.
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ii. Seven of the Polypeptides Were Successfully Expressed
To express the polypeptides using the pET expression system, recombinant
plasmids were transformed into BL21(DE3)pLysS E. coli cells. This strain was selected
because of its successful history for inducible expression of protein/polypeptides in pET
plasmids, the chloramphenicol selection capability, and because this strain codes for
lysosyme, assisting in efficient lysis of cells when purifying a protein of interest. Before
the polypeptides were expressed on a large scale, transformants were screened for
expression on a small scale. 4-6 colonies were selected and grown in 2.0 ml of media
and induced with 1.0mM IPTG. Expression was successfully achieved for seven of the
eight polypeptides: 1-100, 51-150, 101-200, 151-251, 201-300, 251-350, and 351-459,
shown in Figure B.5, which does include the new 251-350 recombinant. The colony from
each recombinant polypeptide that demonstrated the best expression (by visual
assessment) was selected for growth/expression on a large scale in 2.0 L as described.
Expression was detected using an antibody to the His-tag at the N-terminal of the
expressed polypeptide.
Small scale expression of the polypeptides was performed multiple times
throughout the course of this project. Expression levels of each polypeptide were
somewhat variable from one transformation to another, but each demonstrated a (general)
repeatable level of expression in comparison to the other polypeptides. For example,
polypeptides 201-300 and 351-459 consistently expressed at higher levels than either 1100 or 51-150. Inconsistencies in expression are most easily explained by loading
variabilities. Cells are grown in slightly different conditions and post-induction growth
times do vary for individual induction studies. It is very difficult to assess the
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Figure B.5: Expression of Overlapping 100aa Polypeptides
BL21(DE3)pLysS cells containing the recombinant plasmids were induced
to express using 1.0mM IPTG. Crude extracts were loaded on 15% SDS
PAGE and transferred to nitrocellulose. Expression was detected using an
anti-His tag antibody and Western blots are pictured here. Expression was
achieved for all the polypeptides except 301-400. The newly cloned 251350, which had eluded expression previously, did express as shown here.
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concentration of the target polypeptide for each experiment, so a fixed microliter amount
is loaded and inevitably variable expression levels are detected.
Even after successfully cloning 301-400, multiple attempts to express the
polypeptide failed. When the recombinant plasmid was digested with BamHI/NdeI, an
“insert” band was visualized by gel electrophoresis. DNA sequence analysis shows
correct promoter sequence, and the cells supposedly containing the recombinant plasmids
are viable. But this recombinant continues to resist expression.

iii. Purification Was Achieved for Seven Polypeptides
To exploit the N-terminal His-tag on each expressed polypeptide, nickel affinity
chromatography was selected to purify the recombinants. Centrifuged cells were
resuspended and the cells were lysed by sonication. Upon Western analysis, polypeptides
1-100 and 51-150 were found to be present primarily in the “soluble” supernatant, thus
the chromatography described was conducted in the absence of urea. Polypeptides 101200, 151-250, 201-300, 251-350, and 351-459 were resolubilized in 6.0 M urea buffer
and further centrifuged to separate cellular debris. Polypeptide presence was confirmed
by SDS-PAGE/Western blot in the urea-solubilized sonication pellet and the
chromatography performed for these polypeptides included buffers containing 6.0 M
urea. Affinity chromatography was performed at 4oC to hinder degradation per company
suggestion. Polypeptide samples were loaded and washed at a flow rate of 1.0 ml/min
and 3.0 ml fractions were collected and monitored at 280nm till the absorbance was close
to 0.0.
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First attempts at purification with polypeptide 151-250 (found to be a high-yield
recombinant compared to the other polypeptides) employed a protocol with only one
elution step with 300 mM imidazole. This resulted in a polypeptide in solution with
several contaminants. Subsequent purifications were performed with a step-wise elution
of 75, 150, and finally 300 mM imidazole. This yielded much purer polypeptides. SDSPAGE gels for the purification of each polypeptide are shown in Figure B.6. Protein
concentrations for the elution fractions with highest absorbance (280 nm) were
determined using the Bradford Assay, the values of which are listed in Table II. The
expression of 101-200 was low compared to other polypeptides, thus a 3.0 ml fraction of
101-200 was concentrated down to 1.0 ml using an Amicon centrifuge concentrator.
These polypeptides tend to be susceptible to degradation. It was observed that
even 4-5 days after purification, the concentration of a particular polypeptide was
dramatically reduced, probably due to protease degradation. Because of this observation,
a portion of all the eluted polypeptides was immediately reserved, mixed 1:1 with
reducing sample loading buffer, boiled 5 minutes and frozen in the -80oC storage freezer.
Figure B.7 is a 15% SDS-PAGE gel picture of the seven purified polypeptides, along
with relative molecular weight values.

iv. Far Western Conditions Were Optimized
To determine if this assay could feasibly be used with the protein components
involved and also to determine effective Far Western conditions to eventually use in
experiments with the polypeptides, a series of Far Western blots was performed with fulllength vitronectin. Different amounts of vitronectin—0.5µg, 1.0µg, 2.0µg, 3.0µg, 5.0 µg,
52

115 116 117

86 87 88 103

1-100
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Figure B.6: SDS-PAGE of Polypeptide Purifications.
Original supernatants and fractions from different steps of the purification process
were analyzed by SDS-PAGE for each of the polypeptides and gel pictures are
presented here. Purification was achieved using nickel affinity chromatography.
The red squares indicate the polypeptide of interest in each gel picture. Relative
concentrations of pure polypeptides in the noted fractions (red) were assayed
using the Bradford method and a summary is reported in Table II.
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Table II: Relative Concentrations of Purified Polypeptides.
Polypeptide

Fraction #

Concentration (µg/ml)*

1-100

86
87
88
103

97
348
176
211

51-150

115
116
117

71
212
81

101-200

98
100
116
117

5
2
19
53

151-250

96
97
98
99

63
1034
259
64

201-300

104
105
106
107

378
457
106
23

251-350

77
80
83
85
86
87
88
89

167
258
310
374
2459
2763
1432
562

351-459

80
81
82
83

1323
924
421
311

*Concentrations determined using a standard Bradford assay.
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Polypeptide Molecular Weight
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351-459
15,600
full length vitronectin

Figure B.7: Purified Polypeptides of Vitronectin.
This is a 15% SDS-PAGE gel picture of the purified polypeptides. In addition, their
relative molecular weights are listed; these weights include the N-terminal his-tag.
Approximately 10µg total protein was loaded in each lane. Full length vitronectin
was also run in lane 8.
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and 10µg—were loaded on 10% SDS-PAGE and then transferred to nitrocellulose.
Blocking conditions were consistently 10% dry milk in PBS. Different
concentrations/molarities of TAT complex were incubated with the membranes and
allowed to bind at room temperature for 1 hour or overnight at 4oC to determine the better
binding conditions. After incubation with the complex, the membranes were allowed to
bind primary antibodies to thrombin and antithrombin (separate membranes). Dilutions
of the primaries were varied in these optimization experiments to assay both 1:2000 and
1:1000 dilutions. Secondary peroxidase-conjugated antibodies were consistently 1:2000
dilutions. From the optimization experiments (Figure B.8), the best conditions were
determined to be 3µg protein (or comparable ratio of polypeptide), overnight binding of
the complex (200 µl in 30 ml 1% dry milk/PBS) at 4oC, and 1:2000 dilution of the
primaries. Such conditions were necessary to elicit a visual colormetric signal. A
positive result also supported the usage of such a method to study interaction between
vitronectin (or polypeptides) and the thrombin-antithrombin complex.

v. The TAT Complex Localizes to Two Regions on Vitronectin
With an optimized protocol, Far Western experiments were attempted with the
purified polypeptides. Approximately 10-20µg total polypeptide were loaded on 15%
SDS-PAGE with appropriate controls (full-length vitronectin and either thrombin or
antithrombin). The conditions used to produce a positive signal with full-length
vitronectin initially did not give a positive signal with the polypeptides. Vitronectin was
serving as a positive control and it was visualized on each blot, but the polypeptides
failed to indicate any interaction. More Far Western blots were performed, each blot
56

AT
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Vitronectin
3ug 5ug Throm
132,000
78000
45, 700

+
a. anti-Antithrombin
b. anti-Thrombin

Figure B.8: Far Western Results for Native Vitronectin and TAT Interaction.
3µg and 5µg of vitronectin was loaded on 10% SDS-PAGE and transferred to
nitrocellulose. The membrane was blocked for 1 hour in 10% dry milk in PBS and
then allowed to incubate with the thrombin-antithrombin complex overnight at 4oC.
After washing, the membranes were allowed to incubate with either antiantithrombin (a.) or anti-thrombin (b.) primary antibodies diluted 1:2000.
Peroxidase-conjugated secondary antibodies were allowed to bind and then
chromagenic detection was used to visualize the interaction.
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varying one condition: greater amount of total polypeptide was loaded, blocking
conditions were reduced to 5% dry milk in PBS for 45 minutes instead of an hour,
dilution of the primary antibody (to both thrombin and antithrombin) was increased to
1:1000. Still, an interaction was never indicated with the chromagenic development
method routinely employed in this laboratory.
Seeking a more sensitive detection method, Far Western experiments were
performed employing chemiluninescent development techniques. Approximately 10µg
total of each polypeptide was loaded on 10% SDS-PAGE and transferred to Immobilon™
(Millipore) via a submerged transfer apparatus. The blot was blocked 40 minutes in 5%
dry milk TBS/Tween and allowed to incubate with the complex (50 µl 400µg/ml
thrombin:50µl 1.5 mg/ml antithrombin in 30 ml 2.5% dry milk TBS/Tween) overnight at
4oC. After careful washing for 30 minutes total, primary antibodies were diluted
1:25,000 in 2.5% dry milk TBS/Tween and allowed to bind 40 minutes. The membranes
were washed and peroxidase-conjugated secondaries were allowed to bind 40 minutes
(1:25,000 dilution). After careful washing, the membranes were bathed in a
chemiluminescent-specific substrate available from Pierce. The membranes were
exposed to film for 5 minutes, 10 minutes, and 30 minutes and then developed in the dark
room.
The Far Westerns performed and developed with this more sensitive detection
method did reveal some interactions (Figure B.9). The thrombin Far Western (primary
antibody to thrombin) indicates the TAT complex binds to the 151-250 polypeptide and
the 251-350 polypeptide. The antithrombin Far Western gave a signal for four of the
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b. Antithrombin Far Western
Figure B.9: Far Western Results of the Interaction Between Vitronectin
Polypeptides and TAT.
These are 5 minute exposure films of Far Westerns of vitronectin polypeptides
incubated with the thrombin-antithrombin complex. Approximately 10µg of each
polypeptide was loaded on 15% SDS-PAGE and transferred to Immobilon™. Complex
was allowed to bind overnight and then the membrane was incubated with primary
antibodies to both thrombin (a.) and antithrombin (b.) diluted 1:25,000 in 2.5% dry milk
in TBS/Tween. An interaction between the polypeptides and the thrombin-antithrombin
complex is detected by chemilluminescence between polypeptides 151-250 and 251-350
on both blots. In addition, the antithrombin blot indicates an interaction at 201-300 and
351-459. (These are X-ray films after 5 minutes of exposure.)
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polypeptides: 151-250, 201-300, 251-350, and 351-459. The Far Westerns were
repeated and revealed the same interactions.
Even though thrombin and antithrombin form a complex that should be identified
by a primary antibody to either component of the pair, both an antibody to thrombin and
an antibody to antithrombin were employed in the Far Westerns. This was done to be
more thorough in evaluation of TAT interaction and also to corroborate data generated by
each antibody. The thrombin Far Western gave a signal with only two polypeptides,
while the antithrombin Far Western gave a signal with four polypeptides. There are a
number of possibilities to explain this result. The primary antibodies are both polyclonals
that are known to recognize their respective proteins and the TAT complex. The two
additional interactions indicated with the antithrombin antibody could have been a result
of non-specific binding or genuine interactions of vitronectin with the TAT complex.
Perhaps the interaction was not detected with the thrombin antibody due to antibody
interference from association of TAT with the polypeptide.
Thrombin-antithrombin complex formation was achieved by mixing together a
1:1.5 molar ratio of thrombin:antithrombin. Although the thrombin component is
responsible for the interaction of the TAT complex with vitronectin, excess free
antithrombin could have interacted with the polypeptides and then given a false positive
signal upon the addition of antithrombin antibody, although this possibility seems highly
unlikely.
In any event, the 151-250 and 251-350 interactions are corroborated by both
thrombin antibody and antithrombin antibody Far Westerns. The 151-250 polypeptide
lies within the first hemopexin homology domain. The 251-351 spans both hemopexin
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domains and does include part of the heparin binding region where TAT has been
speculated to interact.

IV. Discussion
Vitronectin performs many physiological roles due to its interactions with
multiple ligands. Many of these interactions have been studied extensively to elucidate
vitronectin function. Binding determinants have been concurrently localized, giving
credence to a domain organization of the protein. Ligand-binding regions have been
assigned with a relative degree of confidence from various groups/techniques reporting
similar findings. Heparin-binding to vitronectin is such an example, as well as a highaffinity binding site in the SMB domain for PAI-1. However, the binding region(s) for
the thrombin-antithrombin complex have not been elucidated. The ternary complex
formation of TAT with vitronectin is a very important event that warrants closer
examination. The association of thrombin with antithrombin has been well characterized,
but much is still unknown about what happens when the TAT complex encounters multifunctional vitronectin.
Work with mABs and cleavage products of vitronectin by de Boer et al. suggests
the region on vitronectin responsible for interaction with TAT is the N-terminal region
(16). Earlier studies by the same group demonstrated that the ternary complex bound
endothelial cells via the heparin-binding region of vitronectin, thus this region could not
be involved in the formation of the VN-TAT complex (92). Another site had to be
responsible.
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Although recombinant polypeptides have been used to localize ligand binding
sites on vitronectin for some molecules, they have not been employed in assays with the
thrombin-antithrombin complex. Using bacterial recombinants, this project reports the
possibility of two TAT binding regions on vitronectin, one spanning amino acids 151250, the other amino acids 251-350. Interactions were detected by Far Western, a
technique utilized by many groups to study protein-protein interactions. Two other
points of interaction are reported from the antithrombin antibody Far Western, but these
interactions are not seen in the thrombin Far Western. This does not throw out their
validity as genuine points of interaction, but neither does it strengthen their case.
Far Westerns are derivations of Western blots, and certain limitations exist in
these assays. Results from experiments that capitalize on immobilized protein must be
interpreted carefully. Conformationally-dependent binding determinants are often
undetectable in such assays due to fold disruption. It is also assumed many times when
conducting these experiments that epitopes are independent; multivalency effects are
often lost. Additionally, when electroblotting proteins, it is difficult to determine
accurate amounts or concentrations of proteins that actually end up being assayed.
Furthermore, preparations of the polypeptides and proteins are subject to
consideration. Recombinant expression in E. coli renders a polypeptide devoid of any
post-translational modifications. In some cases, phosphorylation of vitronectin has
proven important for ligand binding. Such knowledge must be noted in any ligandbinding study that utilizes polypeptides devoid of such modifications, such as this one.
Also, when using “pieces” of proteins, whether recombinantly expressed polypeptides,
synthetic peptides, or proteolytic fragments, there is always the possibility that a binding
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site has been disrupted by the separation technique (cleavage or engineering). Assays
with prepared peptides are also often highly susceptible to experimental artifact.
Still, the data collected and reported here has value. The interaction of two
polypeptides suggests two possible binding sites. The stoichiometry of the ternary
complex of VN-T-AT appears to be 1:1:1, although vitronectin has demonstrated
interesting binding stoichiometries with thrombin alone (197). (The ternary complex
migrates at approximately 160kDa in non-reducing condtions.) Detection of two regions
of interaction could suggest a different binding stoichiometry, but it is highly unlikely.
Polypeptide 151-250 spans hemopexin homology domain I. No reports of TAT
binding have been mapped here or ever speculated. The 251-350 polypeptide spans part
of the heparin-binding region, which has been eliminated experimentally as a region for
binding. However, this polypeptide spans 90 amino acids that are not part of the heparin
binding region, so another epitope could very possibly lie within that region.

V. Future Experiments
This work poses two possible regions for TAT interaction with vitronectin.
Further experiments should include competitive binding experiments with monoclonals
of known epitope, a method extensively used and reported in the literature. The
polypeptides should also be examined for binding to thrombin alone. Working under the
assumption that thrombin is the binding component of the TAT pair that interacts with
vitronectin, it would be interesting to see if similar results are discovered. Eventually,
once a polypeptide binds consistently in both Far Westerns and competitive binding
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experiments, work should be done to elucidate specific residues important for binding
using site-directed mutagenesis or synthetic peptides.
A successful purification protocol has been written and tested for each of the
recombinant polypeptides. Pure polypeptides have even reserved and placed in long-term
storage and can be used in any number of subsequent experiments. These polypeptides
have served and will continue to serve as very useful reagents in elucidating information
about vitronectin activity and function.
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Part C
Monoclonal Antibody Characterization and Mapping
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I. Introduction
Monoclonal antibodies are invaluable tools of biochemistry. They are used in a
wide variety of assays to ascertain various kinds of information. Monoclonal antibodies
have proven very important in vitronectin research. They have been used generally to
detect the presence of protein and more specifically to propose and localize the ligand
binding sites of PAI-1 (86,96,102), plasminogen (86), TAT (16,92), collagen (104,198),
complement complex (104), and heparin (104) to vitronectin. For localization of regions
of ligand interaction, it is often advantageous and sometimes necessary to know the
specific region of vitronectin to which a certain antibody maps, such as competition
assays. Thus, when a new monoclonal has been generated, it must be further
characterized to be fully appreciated.
Our laboratory has recently acquired eight murine monoclonal antibodies, one
from Green Mountain, one from Quidel and six from Molecular Innovations (MI).
Cindy Brown, a graduate student in the lab, has performed preliminary experiments with
these antibodies to generally characterize their binding to vitronectin. ELISA results
indicate binding titers for this type of solid-phase assay and help to eliminate weaklybinding monoclonals. HPLC analysis is being conducted to resolve vitronectin-antibody
complexes that can ultimately be isolated and utilized in crystallography trials.
Vitronectin has been titrated at different ratios to antibody and preliminary results for two
of the monoclonals (Quidel and MI-1D1) look promising.
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II. Experimental Procedures
Murine monoclonal antibodies to vitronectin were obtained from Green
Mountain, Quidel, and Molecular Innovations (1D1, 1E9, 2C3, 8H1, 2A10, 4A1).
Secondary peroxidase-conjugated anti-mouse antibodies were purchased from Vector
Laboratories. As a first step, the antibodies were tested for interaction with vitronectin in
Western blotting. 5 µg native vitronectin was loaded on 10% SDS-PAGE and transferred
to nitrocellulose via a BioRad Semi-dry Blotter at 20V for 20 minutes. The blots were
blocked for 1 hour in 10% dry milk in PBS/0.1% Tween and then incubated with the
monoclonals at ELISA-determined titers (as a starting dilution) for 1 hour. After washing,
secondary peroxidase-conjugated anti-mouse antibodies were allowed to bind and
detection was visualized upon addition of peroxide substrate.
Epitope mapping of the antibodies was performed by loading 10 µg of each
polypeptide on 15% SDS-PAGE and performing a Western blot as previously described;
both chromagenic and chemiluminescent development were used. Epitope mapping
experiments were repeated.

III. Results
As a first step in characterizing these monoclonals, it was important to establish
that they could be used in immunoblotting experiments, namely Westerns. A chart
summarizing the ELISA and Western data for the eight monoclonal antibodies is found in
Table III. Three of the eight monoclonals ( 4A1, 2A10, 8H1) were determined to bind
poorly to solid phase vitronectin based on the ELISA experiments. Western blots were
performed with all the antibodies with antibody dilutions determined from the effective
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Table III: Summary of ELISA and Western Results for Monoclonals.
Antibody

ELISA
effective concentration
(µg/ml)*

Western
concentration tested
(µg/ml)

Signal§

Green Mountain

0.052

0.052

+

Quidel

0.6

0.6

+

MI-1D1

0.3

0.3

+

MI-1E9

0.32

0.32

+

MI-2C3

0.86

0.86

+

MI-4A1

---

0.4

+

MI-2A10

---

0.2

---

MI-8H1

---

0.1

---

Eight monoclonal antibodies were assays with native vitronectin in both ELISA experiments
and Western blots. *Cindy Brown performed the ELISA experiments, while Western blots
were incubated with dilutions of the monoclonals based on the effective titers calculated from
the ELISAs. §A “+” denotes a positive interaction between native vitronectin and the
antibody tested, while “---” indicates no interaction.
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ELISA titers or a 1:1000 dilution of the company provided stock. Native vitronectin was
immunoblotted onto nitrocellulose and incubated with the monoclonals. Six (Green
Mountain, Quidel, MI-1D1, MI-1E9, MI-2C3, MI-4A1) of the eight monoclonals gave a
positive signal on the Western blot (Figure C.1a). These six were further characterized
by Western blot with the vitronectin polypeptides.
Approximately 10 µg of each polypeptide was loaded, along with a native
vitronectin control, on 15% SDS-PAGE. The polypeptides were electroblotted first onto
nitrocellulose and incubated with one of the monoclonals. Polypeptide 51-150 gave a
positive signal on the Quidel blot (Figure C.1b), and polypeptides 101-200 and 351-459
gave a positive signal on the MI-2C3 blot (Figure C.1c). 2C3 is a monoclonal antibody,
so the detection of two potential binding sites for 2C3 is suspicious and probably caused
by non-specific binding, although anything is possible when testing “uncharacterized”
tools.
On the blots incubated with Green Mountain, MI-1D1, MI-1E9, and MI-4A1, no
color development resulted except for the full length vitronectin control. A concern arose
that blocking conditions were too severe, so the Westerns were repeated and blocked only
for 45 minutes in 5% milk/PBS, but similar blots resulted with no development. As was
the case for the Far Westerns, a more sensitive detection method was sought after, and
again chemiluminescent development was employed for subsequent Westerns. When
this detection method was used, results for Green Mountain, 1D1, and 1E9 were the
same. No interaction with the polypeptides was detected. This suggests that these
monoclonals recognize epitopes that are conformationally-dependent and structural
binding requirements are disrupted when the polypeptides are prepared or immobilized.
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VN

127,000
85,000

b.

101-200

40,700
31,900
18,700
7500

+

VN

a.

c.

101-200

351-459

Figure C.1: Antibody Mapping.
In (a.), 5.0 µg of full length vitronectin was loaded on 10% SDS-PAGE
and Western blotted to nitrocellulose. The membrane was cut into seven
strips and incubated with seven different murine monoclonal antibodies to
vitronectin. The first five pictured indicated interaction, while the last two
do not. Quidel (b.), MI-2C3 (c.) and MI-4A1 (d.) antibodies were
incubated with blotted polypeptides. Quidel maps to polypeptide 51-150.
2C3 maps to polypeptides 101-200 and 351-459. 4A1 maps to
polypeptides 101-250 and 151-251.
(b.) and (c.) are pictures of
nitrocellulose developed using chromagenic detection. (d.) is a picture of
X-ray film exposed for one minute to Immobilon™ as part of a
chemilluminescent detection protocol.

d.

151-250

VN

101-200
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MI-4A1, however, gave a positive result in binding to polypeptides 101-200 and
151-250 (Figure C.1d). The binding of two consecutive polypeptides is very
encouraging. These polypeptides overlap, and such a pattern of binding could be
interpreted as two binding sites or the same binding within the overlapping region. For
4A1, one binding site could potentially be between 151-200, which localizes the binding
to 50 amino acids instead of 100. Interestingly, on the full length vitronectin control for
2C3, the antibody recognizes the low molecular weight band of the two chain form of
vitronectin, which is usually not visualized by Coomassie staining. This band is a 10kDa
peptide that results from the cleavage at residue 379. I would expect an antibody that
recognizes the low molecular weight band to bind the 351-459 polypeptide, but that is not
the case here.

IV. Discussion
There are several published techniques that have been used to map monoclonal
antibodies to vitronectin, some very direct and some very elegantly designed. The
approach used here is a direct one and capitalizes on the recombinant polypeptides of
vitronectin previously expressed and purified. Eight monoclonal antibodies have been
acquired by this laboratory. Six were found to bind full-length vitronectin in Western
immunoblotting experiments. Green Mountain, MI-1D1, and MI-1E9 do no appear to
have linear epitopes that can be mapped by the method employed here. Three others—
Quidel, MI-2C3, and MI-4A1—seem to bind the polypeptides with high affinity and
recognize linear epitope(s) that have been successfully localized. Quidel maps to 101-
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200; 2C3 interacts with two non-consecutive polypeptides, 101-200 and 351-49; 4A1
maps to 101-200 and 151-250, or is perhaps localized more specifically to 151-200.

V. Future Experiments
In order to acquire epitope information for Green Mountain, 1D1, and 1E9
monoclonal antibodies, native gels should be run with polypeptides or cleavage products
to gain insight on the recognition regions for these monoclonals that did not give a signal
on SDS-PAGE Westerns.
Any of the monoclonals that map with some degree of confidence and consistency
becomes a candidate for co-crystallization trials. These will also be used to study
interactions of vitronectin with its many ligands and generally to detect presence of
protein.
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APPENDIX A: Polypeptide Information
POLYPEPTIDE 1-100
Peptide Sequence
DQESCKGRCT EGFNVDKKCQ CDELCSTTQS CCTDYTAECK PQVTRGDVFT
NPEDEYTVYD DGEEKNNATV HEQVGGPSLT SDLQAQSKGN PEQTPVLKPE
Amino Acid Composition
residue
A
B
C
D
E
F
G
H
I
K
L
M
N
P
Q
R
S
T
V
W
Y
Z

number
3
0
8
9
12
2
10
8
0
7
6
3
4
7
8
3
11
9
8
0
5
0

mole percent
2.439
0.0
6.504
7.317
9.756
1.626
8.130
6.504
0.0
5.691
4.878
2.439
3.252
5.691
6.504
2.439
8.943
7.317
6.504
0.0
4.065
0.0

Molecular Weight (Daltons)
13,679.85
Isoelectric Point
4.88

90

POLYPEPTIDE 51-150
Peptide Sequence
NPEDEYTVYD DGEEKNNATV HEQVGGPSLT SDLQAQSKGN PEQTPVLKPE
EEAPAPEVGA SKPEGIDSRP ETLHPGAPQP PAEEELCSGK PSTLHRLKNG
Amino Acid Composition
residue
A
B
C
D
E
F
G
H
I
K
L
M
N
P
Q
R
S
T
V
W
Y
Z

number
7
0
1
8
16
2
11
9
1
6
8
3
4
15
5
3
11
6
6
0
2
0

mole percent
5.645
0.0
0.806
6.452
12.903
1.613
8.871
7.258
0.806
4.839
6.452
2.419
3.226
12.097
4.032
2.419
8.871
4.839
4.839
0.0
1.613
0.0

Molecular Weight (Daltons)
13,450.48
Isoelectric Point
4.62
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POLYPEPTIDE 101-200
Peptide Sequence
EEAPAPEVGA SKPEGIDSRP ETLHPGAPQP PAEEELCSGK PSTLHRLKNG
SLFAFRGQYC YELDEKAVRP GYPKLIRDVW GIEGPIDAAF TRINCQGKTY
Amino Acid Composition
residue
A
B
C
D
E
F
G
H
I
K
L
M
N
P
Q
R
S
T
V
W
Y
Z

number
9
0
3
6
12
5
13
8
5
6
8
2
2
13
3
7
9
4
4
1
3
0

mole percent
7.317
0.0
2.439
4.878
9.756
4.065
10.569
6.504
4.065
4.878
6.504
1.626
1.626
10.569
2.439
5.691
7.317
3.252
3.252
0.813
2.439
0.0

Molecular Weight (Daltons)
13,512.97
Isoelectric Point
6.30
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POLYPEPTIDE 151-250
Peptide Sequence
SLFAFRGQYC YELDEKAVRP GYPKLIRDVW GIEGPIDAAF TRINCQGKTY
LFKGSQYWRF EDGVLDPDYP RNISDGFDGI PDNVDAALAL PAHSYSGRER
Amino Acid Composition
residue
A
B
C
D
E
F
G
H
I
K
L
M
N
P
Q
R
S
T
V
W
Y
Z

number
8
0
2
11
6
6
14
8
6
4
9
2
4
8
3
8
9
2
5
2
7
0

mole percent
6.452
0.0
1.613
8.871
4.839
4.839
11.290
6.452
4.839
3.226
7.258
1.613
3.226
6.452
2.419
6.452
7.258
1.613
4.032
1.613
5.645
0.0

Molecular Weight (Daltons)
13,948.35
Isoelectric Point
6.30
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POLYPEPTIDE 201-300
Peptide Sequence
LFKGSQYWRF EDGVLDPDYP RNISDGFDGI PDNVDAALAL PAHSYSGRER
VYFFKGKQYW EYQFQHQPSQ EECEGSSLSA VFEHFAMMQR DSWEDIFELL
Amino Acid Composition
residue
A
B
C
D
E
F
G
H
I
K
L
M
N
P
Q
R
S
T
V
W
Y
Z

number
6
0
1
10
10
9
10
10
3
3
8
4
3
6
7
6
13
0
5
3
7
0

mole percent
4.839
0.0
0.806
8.065
8.065
7.258
8.065
8.065
2.419
2.419
6.452
3.226
2.419
4.839
5.645
4.839
10.484
0.0
4.032
2.419
5.645
0.0

Molecular Weight (Daltons)
14,497.77
Isoelectric Point
5.21
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POLYPEPTIDE 251-350
Peptide Sequence
VYFFKGKQYW EYQFQHQPSQ EECEGSSLSA VFEHFAMMQR DSWEDIFELL
FWGRTSAGTR QPQFISRDWH GVPGQVDAAM AGRIYISGMA PRPSLAKKQR
Amino Acid Composition
residue
A
B
C
D
E
F
G
H
I
K
L
M
N
P
Q
R
S
T
V
W
Y
Z

number
7
0
1
5
8
8
11
10
4
4
6
6
0
6
10
8
14
3
5
4
4
0

mole percent
5.654
0.0
0.806
4.032
6.452
6.452
8.871
8.065
3.226
3.226
4.839
4.839
0.0
4.839
8.065
6.452
11.290
2.419
4.032
3.226
3.226
0.0

Molecular Weight (Daltons)
14,364.02
Isoelectric Point
7.38
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POLYPEPTIDE 301-400
Peptide Sequence
FWGRTSAGTR QPQFISRDWH GVPGQVDAAM AGRIYISGMA PRPSLAKKQR
FRHRNRLGYR SQRGHSRGRN QNSRRPSRAT WLSLFSSEES NLGANNYDDY
Amino Acid Composition
residue
A
B
C
D
E
F
G
H
I
K
L
M
N
P
Q
R
S
T
V
W
Y
Z

number
7
0
0
5
3
4
13
10
3
3
7
5
6
6
6
17
17
3
3
3
3
0

mole percent
5.645
0.0
0.0
4.032
2.419
3.226
10.484
8.065
2.419
2.419
5.645
4.032
4.839
4.839
4.839
13.710
13.710
2.419
2.419
2.419
2.419
0.0

Molecular Weight (Daltons)
14,172.67
Isoelectric Point
12.16

96

POLYPEPTIDE 351-459
Peptide Sequence
FRHRNRLGYR SQRGHSRGRN QNSRRPSRAT WLSLFSSEES NLGANNYDDY
RMDWLVPATC EPIQSVFFFS GELYYRVNLR TRRVDTVDPP YPRSIAQYW
LGCPAPGHL
Amino Acid Composition
residue
A
B
C
D
E
F
G
H
I
K
L
M
N
P
Q
R
S
T
V
W
Y
Z

number
5
0
2
7
4
5
10
10
2
2
9
4
7
9
4
18
16
3
6
3
7
0

mole percent
3.759
0.0
1.504
5.263
3.008
3.759
7.519
7.519
1.504
1.504
6.767
3.008
5.263
6.767
3.008
13.534
12.030
2.256
4.511
2.256
5.263
0.0

Molecular Weight (Daltons)
15,594.26
Isoelectric Point
11.08
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APPENDIX B: Polypeptide Modeling
Using INSIGHT© software, the following polypeptides were highlighted in the predicted
three-dimensional structure of vitronectin determined by Xu et al (2001).

151-250

201-300
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301-400

351-459
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APPENDIX C: Domain Organization of Vitronectin
N-terminal Domain

DQ▼ESCKGRCTEGFNVDKKCQCDELCSYYQSCCTDY
TAECKPQ▼VT
Connecting Region

RGDVFTMPEDEYTVYDDGEEKNNATVHERVGGPSLTSDLQAQS
KGNPEQTPALKPEEEAPAPEVGASKP▼EGIDSRPET
Hemopexin Homology Domain I

LHPGRPQPPAEEELCSGKPFDAFTDLKNGSLFAFR▼
GQYCYELDEKAVRPGYPKLIRDVW
GIEGPIDAAFTRINCQGKTYLFK▼GSQYWRFEDGVLDPDYPRNI
SDGFDGIPDNADAAL
ALPAHSYSGRERVYFFK▼GKQYWEYQFQHQPSQEECEGSSLSA
VFEHFAMMQRDS
EDIFELLFWGRTS▼AGTRQPQFISRDWHGV
Hemopexin Homology Domain II

PGQVDAAMAGRIYISGMAPRPSLAKKQRFR
HRNRKGYRSQRGHSRGRNQNSRRPSRATWLSLFSSEESNLGANN
YDDYRMDWLVPATCE
PIQSVFFFSG▼DKYYRVNLRTRRVDTVDPPYPRSIAQYWLGCPA
PGHL
This is the mature vitronectin peptide sequence organized into four domains.
Green indicates the N-terminal domain, gray is the connecting region, orange
represents hemopexin homology domain (HPD) I, and blue is hemopexin
homology domain II. An ▼ indicates an exon junction. HPD I and II are
further organized into four and three parts, respectively, to indicate individual
“blades” of the predicted ß-propeller structure (Xu et al, 2001).
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